The Business Gazette Online
SEE OTHER BRANDS

Bringing you the latest news on business and economy

EDAP to Participate in the UBS Global Healthcare Conference


 EDAP to Participate in the UBS Global Healthcare Conference

Company to Host 1x1 Investor Meetings on Monday, November 10th, 2025

AUSTIN, Texas, October 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, and Ken Mobeck, Chief Financial Officer, are scheduled to host 1x1 investor meetings at the upcoming UBS Global Healthcare Conference, which is being held November 10-13, 2025, in Palm Beach Gardens, Florida.

Date:                    Monday, November 10th

Format:               1x1 investor meetings

Location:               PGA National Resort Hotel, Palm Beach Gardens, Florida

Registration:         Click here to register for the conference (for UBS clients only), or please contact your UBS sales representative.         

        

About EDAP TMS SA

A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/.

Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com


Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions